Clinical trials: Head and Neck Tumor
Esophageal Cancer, Esophageal Squamous Cell Carcinoma
Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to learn if adding high-dose-rate (HDR) brachytherapy can improve outcomes in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who have already received external beam…
- Trial name
- BRIGHT-ESCC (NCT07152678)
- Testing
- Nivolumab (240 mg), Brachytherapy
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Radiation Dermatitis, Head and Neck Cancer
Deep Learning-based Classification and Prediction of Radiation Dermatitis in Head and Neck Patients
to develop a deep learning-based model to grade the severity of radiation dermatitis (RD) and predict the severity of radiation dermatitis in patients with head and neck cancer undergoing radiotherapy, so as to provide support…
- Trial name
- NCT05607225
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma
Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
This study is a prospective, single-arm, single-center Phase Ib clinical trial of Becotatug Vedotin in combination with cisplatin and concurrent radiotherapy for locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT07697040
- Testing
- Becotatug Vedotin Combined with Cisplatin and Concurrent Radiotherapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Hebei Medical University Fourth Hospital
Head and Neck Neoplasms
Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors
This study will investigate the efficacy and safety of recombinant human endostatin adenovirus combined with chemotherapy for advanced head and neck malignant tumors.
- Trial name
- NCT02283489
- Testing
- recombinant human endostatin adenovirus, Cisplatin injection, Paclitaxel injection
- Where
- 4 sites in China
- Volunteers
- 180 people
- Sponsor
- Renmiao Zhang
Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
This is a phase II randomized, open label study of durvalumab with/ without tremelimumab as neoadjuvant therapy and durvalumab maintenance after SoC RTx with/without cisplatin as post-surgical adjuvant therapy in treatment naïve…
- Conditions
- Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx, Oropharynx, Larynx
- Trial name
- NCT03737968
- Testing
- Durvalumab, durvalumab + tremelimumab
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Tumor of Ear, Nose and Throat
Conditions of Diagnostic Panendoscopy of the Upper Airway Under Propofol Remifentanil General Anesthesia
The most important considerations for the general anesthesia in diagnostic panendoscopy of the upper airway is the maintenance of a patient's airway for optimal surgical exposure, adequate ventilation and sufficient depth of…
- Trial name
- ENDOTANIL (NCT02093143)
- Testing
- Remifentanil
- Where
- 2 sites in France
- Volunteers
- 256 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Head and Neck Cancer
Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx
RATIONALE: Biological therapies, such as tadalafil, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00843635
- Testing
- Tadalafil
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Donald T. Weed
Esophageal Squamous Cell Carcinoma
Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma
Esophageal cancer is a common malignant disease worldwide especially in china. Though esophagectomy and definitive chemoradiotherapy are standard treatments, disease relapses in many patients and the prognosis of metastatic ESCC…
- Trial name
- NCT03251417
- Testing
- Irinotecan, Apatinib
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Peking University
Nasopharyngeal Carcinoma
BGT007 Cell Treatment of Nasopharyngeal Carcinoma
This is an exploratory study to evaluate the safety and preliminary effectiveness of BGT007 cells in the treatment of recurrent/metastatic nasopharyngeal carcinoma
- Trial name
- NCT05616468
- Testing
- BGT007 Cell Injection, Fludarabine, cyclophosphamide
- Where
- China
- Volunteers
- 23 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Breast Cancer, Non-small Cell Lung Cancer
Study to Evaluate the Safety of Nanoxel M Inj.
Study to evaluate the safety of Nanoxel M inj. administration in patients.
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer
- Trial name
- NCT04066335
- Where
- South Korea
- Volunteers
- 1,498 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Head and Neck Cancer
A Randomized Comparative Study of a Weekly Versus Every Other Week Nurse Practitioner-led Symptom Management Clinic for Head and Neck Cancer Patients Undergoing Concurrent Chemotherapy and Radiation
A retrospective chart review of patients receiving concurrent chemoradiotherapy for oropharynx cancer was performed to compare clinical data for patients treated prior to the initiation of the NP clinic with those subsequently…
- Trial name
- NCT02085525
- Testing
- Nurse Practitioner Clinic
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
Esophageal Squamous Cell Carcinoma (ESCC)
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of sintilimab combined with chemotherapy, followed by sequential concurrent chemoradiotherapy as conversion therapy, in…
- Trial name
- NCT06709417
- Testing
- Sintilimab, Chemotherapy, radiotherapy
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Shanghai Chest Hospital
Carcinoma, Squamous Cell, Head and Neck Cancer
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
Patients will receive standard of care radiation therapy to the primary tumor of the head and neck and involved nodal metastasis and draining nodal basin and either weekly cisplatin or every 3-week cisplatin in locally advanced…
- Trial name
- NCT02994069
- Testing
- Cisplatin, XRT
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Susanne Arnold
Thyroid Cancer
The Effect of the Number of Central Lymph Nodes on Changes in Parathyroid Function
This study collected data from patients who underwent thyroidectomy in the Breast and Thyroid Surgery Department of Shandong Provincial Hospital from January 2020 to December 2023 by reviewing medical records.
- Trial name
- NCT06432244
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Shandong Provincial Hospital
Head and Neck Squamous Cell Carcinoma
Prospective Pilot Study Evaluating Dental Side Effects of Radiotherapy on Subjects Treated for Head and Neck Cancer
Multi-centric, one arm phase II study. The first phase of the study will consist of an evaluation of the initial dental state of each subject based on a stomatological examination, an orthopantomogram, two bitewing radiographs…
- Trial name
- StomRay (NCT04452032)
- Testing
- Dental avulsion, Radiotherapy
- Where
- 3 sites in Belgium
- Volunteers
- 40 people
- Sponsor
- Jules Bordet Institute
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma
A Randomized, Phase II Study of MRG003 in Combination With Pucotenlimab Injection ± Cisplatin in Patients With Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT06530914
- Testing
- MRG003 combined with Pucotenlimab, MRG003 combined with Pucotenlimab+Cisplatin
- Volunteers
- 30 people
- Sponsor
- Lei Liu
Head and Neck Cancer
Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
The goal of this clinical research study is to find the highest safe dose of the drugs OSI-774 and docetaxel that can be given together along with radiation treatment for advanced head and neck cancer.
- Trial name
- NCT00113347
- Testing
- Erlotinib, Docetaxel, Radiation Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Oropharynx Squamous Cell Carcinoma
Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer (MER-HPV)
The goal of this clinical trial is to determine the value of circulating tumour HPV DNA (human papilloma virus DNA found in the blood) at diagnosis, during treatment, and in the follow-up of patients diagnosed and treated for…
- Trial name
- MER-HPV (NCT05649865)
- Testing
- Blood sample
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Region Skane
Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
This phase II trial studies how well cabozantinib, nivolumab, and ipilimumab work in treating patients with differentiated thyroid cancer that does not respond to radioactive iodine and that worsened after treatment with a drug…
- Conditions
- Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma
- Trial name
- NCT03914300
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 33 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Patients will be treated with pembrolizumab after concurrent chemoradiotherapy with cisplatin. Patients will be treated with up to 17 cycles (approximately 1 year) of pembrolizumab until disease progression or recurrence
- Trial name
- NCT04227509
- Testing
- Pembrolizumab
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Seoul National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.